New gene therapy CREPT-618 enters human trials for liver cancer

NCT ID NCT07364357

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial is testing a new drug called CREPT-618 in 13 adults with advanced liver cancer who have not responded to standard treatments. The drug works by targeting a gene called CREPT, which may help control tumor growth. The main goals are to check safety, find the right dose, and see early signs of anti-cancer activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CREPT-618 (a small nucleic acid drug targeting the CREPT gene)
What this could lead to
If this early trial shows safety and hints of tumor shrinkage, it could point toward a new treatment option for advanced liver cancer patients who have run out of standard therapies.
What could go wrong
This is a very early Phase 1 study with only 13 participants, focused mainly on safety and dosing. It is too small and early to know if CREPT-618 will actually work against liver cancer, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    RECRUITING

    Beijing, 100021, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.